Mathew Lozinski1,2,3, Nikola A Bowden2,3,4, Moira C Graves2,3,4, Michael Fay2,3,5, Paul A Tooney6,7,8. 1. School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Newcastle, NSW, Australia. 2. Centre for Drug Repurposing and Medicines Research, University of Newcastle, Newcastle, NSW, Australia. 3. Hunter Medical Research Institute, Newcastle, NSW, Australia. 4. School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle, Newcastle, NSW, Australia. 5. Genesis Cancer Care, Gateshead, New South Wales, Australia. 6. School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Newcastle, NSW, Australia. paul.tooney@newcastle.edu.au. 7. Centre for Drug Repurposing and Medicines Research, University of Newcastle, Newcastle, NSW, Australia. paul.tooney@newcastle.edu.au. 8. Hunter Medical Research Institute, Newcastle, NSW, Australia. paul.tooney@newcastle.edu.au.
Abstract
BACKGROUND: The aggressive, invasive and treatment resistant nature of glioblastoma makes it one of the most lethal cancers in humans. Total surgical resection is difficult, and a combination of radiation and chemotherapy is used to treat the remaining invasive cells beyond the tumour border by inducing DNA damage and activating cell death pathways in glioblastoma cells. Unfortunately, recurrence is common and a major hurdle in treatment, often met with a more aggressive and treatment resistant tumour. A mechanism of resistance is the response of DNA repair pathways upon treatment-induced DNA damage, which enact cell-cycle arrest and repair of DNA damage that would otherwise cause cell death in tumour cells. CONCLUSIONS: In this review, we discuss the significance of DNA repair mechanisms in tumour formation, aggression and treatment resistance. We identify an underlying trend in the literature, wherein alterations in DNA repair pathways facilitate glioma progression, while established high-grade gliomas benefit from constitutively active DNA repair pathways in the repair of treatment-induced DNA damage. We also consider the clinical feasibility of inhibiting DNA repair in glioblastoma and current strategies of using DNA repair inhibitors as agents in combination with chemotherapy, radiation or immunotherapy. Finally, the importance of blood-brain barrier penetrance when designing novel small-molecule inhibitors is discussed.
BACKGROUND: The aggressive, invasive and treatment resistant nature of glioblastoma makes it one of the most lethal cancers in humans. Total surgical resection is difficult, and a combination of radiation and chemotherapy is used to treat the remaining invasive cells beyond the tumour border by inducing DNA damage and activating cell death pathways in glioblastoma cells. Unfortunately, recurrence is common and a major hurdle in treatment, often met with a more aggressive and treatment resistant tumour. A mechanism of resistance is the response of DNA repair pathways upon treatment-induced DNA damage, which enact cell-cycle arrest and repair of DNA damage that would otherwise cause cell death in tumour cells. CONCLUSIONS: In this review, we discuss the significance of DNA repair mechanisms in tumour formation, aggression and treatment resistance. We identify an underlying trend in the literature, wherein alterations in DNA repair pathways facilitate glioma progression, while established high-grade gliomas benefit from constitutively active DNA repair pathways in the repair of treatment-induced DNA damage. We also consider the clinical feasibility of inhibiting DNA repair in glioblastoma and current strategies of using DNA repair inhibitors as agents in combination with chemotherapy, radiation or immunotherapy. Finally, the importance of blood-brain barrier penetrance when designing novel small-molecule inhibitors is discussed.
Authors: J S Loeffler; E Alexander; F H Hochberg; P Y Wen; J H Morris; W C Schoene; R L Siddon; R H Morse; P M Black Journal: Int J Radiat Oncol Biol Phys Date: 1990-12 Impact factor: 7.038
Authors: Mathew Lozinski; Nikola A Bowden; Moira C Graves; Michael Fay; Bryan W Day; Brett W Stringer; Paul A Tooney Journal: Cells Date: 2022-04-04 Impact factor: 6.600
Authors: Leon Emanuel Schnöller; Valerie Albrecht; Nikko Brix; Alexander Edward Nieto; Daniel Felix Fleischmann; Maximilian Niyazi; Julia Hess; Claus Belka; Kristian Unger; Kirsten Lauber; Michael Orth Journal: Radiat Oncol Date: 2022-04-19 Impact factor: 4.309